Lung cancer is one of the most prevalent malignancies with the highest morbidity and mortality rates worldwide. In recent years, with the development of immune-oncology research and several therapeutic antibodies have reach the clinic, many breakthroughs have been made in immunotherapy. The advent of immunotherapy has revolutionized the treatment of NSCLC, but the response and durable clinical benefit are only observed in a small subset of patients. Therefore, strategies to screen the potential beneficial population and improve the efficacy of immunotherapy remain an essential topic. In the current article, the author review the biomarkers that have potential to better predict responders to immunotherapy and to provide ideas for the clinical application of immunotherapy. .
【中文题目：非小细胞肺癌免疫治疗生物标志物研究进展】 【中文摘要：肺癌是最常见的恶性肿瘤之一，其发病率和死亡率位居所有恶性肿瘤首位。近年来，随着肿瘤免疫学的迅速发展，以细胞毒性T淋巴细胞相关蛋白4（cytotoxic T lymphocyte-associated antigen-4, CTLA-4）、程序性细胞死亡蛋白1（programmed cell death-1, PD-1）/程序性细胞死亡配体1（programmed cell death ligand 1, PD-L1）为靶点的免疫检查点抑制剂（immune checkpoint inhibitors, ICIs）不断进入临床实践，标志着免疫治疗的重大突破。免疫治疗的出现彻底改变了非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗现状，但仅有少部分患者能从中持久性获益。因此，如何筛选免疫治疗的获益人群，进一步提高免疫治疗的疗效是当下研究热点。本文聚焦NSCLC免疫治疗相关的生物标记物，并对近年NSCLC免疫治疗生物标志物研究现状和进展进行综述，为免疫治疗的临床实践提供参考。 】 【中文关键词：非小细胞肺癌；免疫治疗；生物标志物；PD-L1；TMB】.
Keywords: Biomarker; Immunotherapy; NSCLC; PD-L1; TMB.